NOVELION THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
NOVELION THERAPEUTICS INC. - More news...
NOVELION THERAPEUTICS INC. - More news...
- Novelion Therapeutics Subsidiary Enters Into Term Loan Agreement and Novelion Provides Business Update
- Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
- Novelion Therapeutics Announces Next Phase of Operational Improvements
- Novelion Therapeutics Reports Second Quarter 2018 Financial Results
- Novelion Therapeutics Announces Marketing Authorization for MYALEPTA® (metreleptin) in the European Union to Treat Generalized and Partial Lipodystrophy
- Novelion Therapeutics Appoints Mark Corrigan, M.D. as Executive Chair of the Board of Directors
- Novelion Therapeutics Announces Presentation of Positive Metreleptin Data at American Diabetes Association Scientific Sessions
- MYALEPTA® (metreleptin) Receives Positive CHMP Opinion in Patients with Generalized and Partial Lipodystrophy
- Novelion Therapeutics Reports First Quarter 2018 Financial Results
- Novelion Therapeutics Supports World Lipodystrophy Day
- Novelion Therapeutics Observes Rare Disease Day
- Novelion Therapeutics Provides Update on Agreement between Aegerion Pharmaceuticals and U.S. Department of Justice
- Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change
- Novelion Therapeutics Expands Leadership Team with Appointment of Jeffrey Hackman as Chief Operating Officer
- Novelion Therapeutics Strengthens Leadership Team with Appointment of Murray Stewart, M.D., as Executive Vice President, Head of R&D
- Novelion Therapeutics Observes Familial Hypercholesterolemia Awareness Day
- Metreleptin and Lipodystrophy Data Presented at the International Meeting of Pediatric Endocrinology
- Novelion Therapeutics Appoints Suzanne Bruhn, Ph.D. to Board of Directors
- Novelion Therapeutics to Announce Second Quarter 2017 Financial Results on August 8, 2017
- Novelion Therapeutics Added to the Russell 3000® & Russell Microcap® Indexes
- Novelion Therapeutics Announces Presentation of Metreleptin Data at American Diabetes Association
- Novelion Therapeutics Appoints John J. Orloff, M.D., to Its Board of Directors, Steps Down as EVP, Head of R&D
- Novelion Therapeutics Reports First Quarter 2017 Financial Results
- Investor Network: Novelion Therapeutics Inc. to Host Earnings Call
- Novelion Therapeutics Announces Presentation of Metreleptin Data at American Association of Clinical Endocrinology
- Novelion Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017
- Novelion Therapeutics Announces Presentation at the Bloom Burton & Co. Healthcare Investor Conference
- Novelion Therapeutics’ Request to Voluntarily Delist from the Toronto Stock Exchange Granted
- Metreleptin and Lipodystrophy Data Presented at the Annual Meeting of the Endocrine Society
- Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors